D. E. Shaw & Co. Inc. Buys 487,844 Shares of Qiagen NV (NYSE:QGEN)

Share on StockTwits

D. E. Shaw & Co. Inc. raised its stake in Qiagen NV (NYSE:QGEN) by 28.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,195,033 shares of the company’s stock after purchasing an additional 487,844 shares during the period. D. E. Shaw & Co. Inc. owned 0.97% of Qiagen worth $89,011,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. M&T Bank Corp increased its stake in Qiagen by 45.4% in the second quarter. M&T Bank Corp now owns 8,230 shares of the company’s stock valued at $333,000 after purchasing an additional 2,568 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in shares of Qiagen during the first quarter worth about $229,000. PNC Financial Services Group Inc. increased its position in shares of Qiagen by 1.8% during the first quarter. PNC Financial Services Group Inc. now owns 205,337 shares of the company’s stock worth $8,353,000 after acquiring an additional 3,609 shares in the last quarter. Cornerstone Advisors Inc. bought a new stake in shares of Qiagen during the first quarter worth about $44,000. Finally, Martingale Asset Management L P increased its position in shares of Qiagen by 2,044.8% during the first quarter. Martingale Asset Management L P now owns 494,619 shares of the company’s stock worth $20,122,000 after acquiring an additional 471,558 shares in the last quarter. 62.10% of the stock is owned by hedge funds and other institutional investors.

QGEN stock traded down $0.15 during trading on Friday, reaching $33.67. The stock had a trading volume of 754,325 shares, compared to its average volume of 854,158. Qiagen NV has a one year low of $32.33 and a one year high of $41.55. The company has a quick ratio of 1.59, a current ratio of 1.77 and a debt-to-equity ratio of 0.54. The company’s 50 day moving average is $34.91 and its two-hundred day moving average is $38.19. The company has a market capitalization of $7.68 billion, a price-to-earnings ratio of 25.13, a P/E/G ratio of 2.09 and a beta of 0.88.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, July 24th. The company reported $0.33 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.01). Qiagen had a return on equity of 12.10% and a net margin of 12.94%. The firm had revenue of $381.60 million during the quarter, compared to the consensus estimate of $386.37 million. During the same period in the previous year, the company posted $0.33 earnings per share. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. As a group, research analysts predict that Qiagen NV will post 1.41 earnings per share for the current fiscal year.

Several equities research analysts have recently commented on the stock. Wolfe Research assumed coverage on shares of Qiagen in a research report on Thursday, May 30th. They set a “peer perform” rating for the company. Berenberg Bank reissued a “buy” rating and set a $40.00 target price on shares of Qiagen in a research report on Friday, July 26th. Exane BNP Paribas raised shares of Qiagen from a “neutral” rating to an “outperform” rating in a research report on Friday, July 12th. Goldman Sachs Group reissued a “buy” rating on shares of Qiagen in a research report on Thursday, August 1st. Finally, Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research report on Friday, July 26th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $41.67.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Recommended Story: What is meant by a buy rating?

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Downgrades Tufin Software Technologies  to Sell
Zacks Investment Research Downgrades Tufin Software Technologies to Sell
Piper Jaffray Companies Lowers Tesla  Price Target to $372.00
Piper Jaffray Companies Lowers Tesla Price Target to $372.00
Raymond James Boosts Intuitive Surgical  Price Target to $625.00
Raymond James Boosts Intuitive Surgical Price Target to $625.00
Assenagon Asset Management S.A. Invests $1.82 Million in Sientra Inc
Assenagon Asset Management S.A. Invests $1.82 Million in Sientra Inc
Assenagon Asset Management S.A. Sells 38,366 Shares of DSP Group, Inc.
Assenagon Asset Management S.A. Sells 38,366 Shares of DSP Group, Inc.
24,885 Shares in Neurocrine Biosciences, Inc.  Acquired by Assenagon Asset Management S.A.
24,885 Shares in Neurocrine Biosciences, Inc. Acquired by Assenagon Asset Management S.A.


© 2006-2019 Ticker Report